

Europe opens largest manufacturing facility for microbiome ecosystem therapies

12 September 2023 | News

Enhancing bioproduction capabilities and contributing to the ecosystem in France and Europe

MaaT Pharma, a clinical-stage biotech company and a leader in the development of Microbiome Ecosystem Therapies (MET) dedicated to improving survival outcomes for patients with cancer, and Skyepharma, a French independent CDMO, expert in providing innovative solutions for bioproduction as well as complex drugs development and manufacturing, have announced that a significant development milestone has been reached with the completion of the facility and the transfer of MaaT Pharma's Production and Development teams to the new site. The companies had entered a partnership in February 2022 to build the largest cGMP facility, to date, for full ecosystem microbiome therapies in Europe.

MaaT Pharma, the leading microbiome company in oncology, is one of the few end-to-end microbiome companies that oversees the entire process, including innovative bioprocesses for both donor-derived and co-cultured drug candidates in a GMP environment.

The completion of this new infrastructure brings with it positive impacts for the regional and national economy. Overall, the partnership between MaaT Pharma and Skyepharma could lead to the creation of a dozen jobs for specialized workers in the industry over the coming years. These therapies demand advanced manufacturing techniques and procedures and will contribute to the growth of the microbiome sector in France. MaaT Pharma and Skyepharma are currently performing quality qualification according to GMP guidelines, with the first production campaign targeted to start in the new plant by the end of Q3 2023.